Tomicić Maja, Vuk Tomislav, Hundrić-Haspl Zeljka
Lijec Vjesn. 2014 Mar-Apr;136(3-4):90-3.
For more than 40 years now, platelet transfusion has provided life-saving supportive therapy to hematological patients with impaired hematopoiesis, bone marrow aplasia induced by chemotherapy, surgical patients and patients with a variety of disorders of platelet count and function. More than 2.9 million platelet components are transfused each year in Europe and 57000 in Croatia. Patients with thrombocytopenia and coagulopathy treated at intensive care units pose special challenges. It is essential to assess the potential risk of thrombogenic side effects over the benefit of stopping and preventing bleeding before platelet transfusion in these patients. Although transfusion practices including indications and contraindications for transfusion, the dose of platelets transfused and ztransfusion trigger' are variable and in some cases the best practices are not fully known, greater harmonization of policies might promote the quality, safety and optimal use of platelet products.
40多年来，血小板输注一直为造血功能受损的血液病患者、化疗引起的骨髓再生障碍患者、外科手术患者以及各种血小板计数和功能紊乱的患者提供挽救生命的支持性治疗。欧洲每年输注超过290万个血小板成分，克罗地亚为57000个。在重症监护病房接受治疗的血小板减少症和凝血病患者面临特殊挑战。在这些患者中，在进行血小板输注之前，评估血栓形成副作用的潜在风险相对于停止和预防出血的益处至关重要。尽管输血实践（包括输血的适应症和禁忌症、输注的血小板剂量以及“输血触发因素”）各不相同，在某些情况下最佳做法也不完全清楚，但政策的更大协调可能会提高血小板产品的质量、安全性和最佳使用效果。
